medRxiv PreprintsInternational17 November 2026
Phase I Clinical Trial of Allogeneic Cytomegalovirus-specific T Cells in Combination with Pembrolizumab for Recurrent Glioblastoma
This is an official announcement record
Firsthand records what medRxiv Preprints announced and links to the original. The wording below is theirs, not ours.
Purpose: Glioblastoma (GBM) remains refractory to immunotherapy due to its immunosuppressive microenvironment. Tumour-infiltrating cytomegalovirus (CMV)-specific T cells express elevated programmed cell death protein-1 (PD-1), suggesting checkpoint-mediated dysfunction may limit T-cell therapy. We evaluated the safety and immunological activity of allogeneic CMV-specific T-cell therapy (CYT-101) combined with pembrolizumab. Patients and Methods: In this phase I 3+3 dose-escalation study, recurrent GBM patients received four weekly infusions of CYT-101 followed by pembrolizumab. The primary end
Read the official announcement
Opens www.medrxiv.org
More from medRxiv Preprints
- Unmet needs of Polish patients with cystic fibrosis seen through the lens of crowdfunding20 November 2026
- Motherly Plus: Study Protocol of a Randomized Controlled Trial Evaluating a Smartphone-Assisted Single-Session Psychotherapy Intervention for Postpartum Depression20 November 2026
- Targeting memory consolidation in major depression via pharmacological slow-wave sleep promotion20 November 2026
- Epidemiology of Cardiac Structure and Function Among African Caribbeans in Tobago: A Population-based Cohort Study20 November 2026
- Depressive Symptom Trajectories and Incident Cognitive Impairment by Outcome Ascertainment20 November 2026
This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.